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Edited by Laszlo NagyAbstract Neuroblastoma (NBL), derived from the sympathetic
precursor cells, is one of the most common pediatric solid tu-
mors. The expression of N-acetylglucosaminyltransferase V
and IX (GnT-V and GnT-IX) mRNA in 126 primary NBLs were
quantitatively analyzed and higher expression levels of GnT-V
were found to be associated with favorable stages (1, 2 and
4s). Conversely, the downregulation of GnT-V expression by
small interfering RNA resulted in a decrease in the susceptibility
to cell apoptosis induced by retinoic acid in NBL cells accompa-
nied by morphological change. These results suggest that GnT-V
is associated with prognosis by modulating the sensitivity of
NBLs to apoptosis.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Apoptosis1. Introduction
Aberrant glycosylation occurs in nearly all types of cancers,
and has been implicated in the malignancy that is characteristic
of the disease [1]. N-acetylglucosaminyltransferase V (GnT-V)
is one of the most relevant glycosyltransferases to tumor inva-
sion and metastasis, and catalyzes the formation of b1,6Glc-
NAc branching on N-glycans, which is closely associated
with malignant transformations [2–6]. Recently, our group
and Pierce’s group independently reported on a new N-acetyl-
glucosaminyltransferase IX (GnT-IX, also referred to as GnT-
VB), a GnT-V homolog, that is speciﬁcally expressed in the
brain [7,8]. GnT-IX transcripts are exclusively expressed in
the brain and testis, while GnT-V is expressed ubiquitously
in human and mouse tissues. Since both glycosyltransferases
are expressed in the mouse brain in a region-speciﬁc manner
(unpublished data), it is possible that they may have discrete
biological functions in the brain. On the other hand, GnT-V
and GnT-IX are both highly expressed in both the adult andAbbreviations: NBL, neuroblastoma; GnT-V, N-acetylglucosaminyl-
transferase V; GnT-IX, N-acetylglucosaminyltransferase IX; RT,
reverse transcription; PARP, poly(ADP-ribose) polymerase
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doi:10.1016/j.febslet.2005.12.089fetal brain [7,9], as well as in several human neuroblastoma
(NBL) cell lines (this study and unpublished data). This
prompted us to examine the expression of GnT-V and GnT-
IX in primary NBL tissues.
NBL is a tumor derived from primitive cells of the sympa-
thetic nervous system and is the most common solid tumor
in childhood [10]. Interestingly, most NBLs in infants regress
spontaneously or mature into a benign ganglioneuroma.
These tumors usually express high levels of TrkA, and as
a result, have a tendency to either undergo apoptosis or dif-
ferentiation, depending on whether nerve growth factor is
present or absent in their microenvironment. On the other
hand, in most patients over 1 year of age who have meta-
static disease, the tumor grows aggressively and their prog-
nosis is usually poor.
In this study, we carried out a quantitative analysis of the
gene expression of these glycosyltransferases by real-time
PCR, and the ﬁndings indicate that a higher expression of
GnT-V is correlated with a favorable prognosis for NBL pa-
tients. Furthermore, to explore the underlying molecular
mechanism, we devised a knockdown approach, in which
small interfering RNA (siRNA)-directed against GnT-V
mRNA was used to investigate the susceptibility to cell
apoptosis induced by retinoic acid in NBL cells. The results
clearly showed that the expression levels of GnT-V are asso-
ciated with a favorable prognosis, possibly through sensitiz-
ing to apoptotic signals.2. Materials and methods
2.1. RNA isolation from primary NBLs
Fresh, frozen tumor tissues were sent to the Division of Biochemis-
try, Chiba Cancer Center Research Institute, from various hospitals in
Japan with informed consent from the patients’ parents. All samples
were obtained by surgery or biopsy and had been stored at 80 C.
The RNA samples obtained from 126 patients with NBL were sub-
jected to semiquantitative and quantitative real-time reverse transcrip-
tion-PCR (RT-PCR) analyses. All of the patients were diagnosed
clinically as well as pathologically and were tested for DNA ploidy,
MYCN ampliﬁcation, and TrkA expression. The tumors were staged
according to the criteria of the International Neuroblastoma Staging
System [11].
2.2. Semiquantitative RT-PCR analysis of primary NBLs
The preparation of total RNA from NBL tissues and the synthesis of
the ﬁrst-strand cDNA were performed as described previously [12].
The cDNA was diluted to a 1:20 solution and then ampliﬁed in a ﬁnalblished by Elsevier B.V. All rights reserved.
Fig. 1. Semiquantitative RT-PCR analysis of favorable and unfavor-
able subsets of NBL. Sixteen favorable cases were in stage 1 with no
MYCN ampliﬁcation and a high TrkA expression, while 16 unfavor-
able cases were in stage 3 or 4 with MYCN ampliﬁcation and a low
TrkA expression.
Table 1
Association of tumor stages and TrkA expression in NBL patients with
GnT-V or GnT-IX mRNA expression levels
n GnT-Va P GnT-IXa P
Tumor stage
1, 2, 4s 57 2.23 ± 0.29 0.021 1.78 ± 0.25 0.21
3, 4 69 1.48 ± 0.16 2.23 ± 0.25
TrkA expression
High 59 2.11 ± 0.27 0.010 1.86 ± 0.17 0.75
Low 48 1.33 ± 0.13 1.98 ± 0.34
aMeans ± S.E.M.
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PCR buﬀer, 0.5 lM of each primer and 0.2 U of rTaq DNA polymer-
ase (Takara Bio, Ohtsu, Japan). The following primer sets were used:
GnT-V, 5 0-GACCTGCAGTTCCTTCTTCG-30 and 5 0-CCATGGCA-
GAAGTCCTGTTT-3 0; GnT-IX, 5 0-CATGGCACCGTGTACTAC-3 0
and 5 0-TCTGGAGCTCTGCAGAAG-30. PCR templates were stan-
dardized by their GAPDH expression before performing the RT-PCR
experiments.
2.3. Quantitative real-time PCR analysis of primary NBLs
2 ll of cDNA prepared as above, either a 100-fold dilution for
GnT-V or a 20-fold dilution for GnT-IX, was ampliﬁed in a volume
of 20 ll with Assay-on-Demand Gene Expression Products (Applied
Biosystems) consisting of primers and a TaqMan probe (Assay ID:
GnT-V, Hs00159136_m1; GnT-IX, Hs01586304_g1). The thermal
cycling conditions and the normalization of the data using GAPDH
expression were performed as described previously [12]. All experi-
ments were carried out in triplicate for each data point.
2.4. Assay of GlcNAc transferase activity
The activities of GnT-V and GnT-III in whole cell lysates or
microsomal fractions were determined using a pyridylaminated bian-
tennary sugar chain as an acceptor substrate, as described previously
[7,13].
2.5. Construction of siRNA vector and retroviral infection
Small interfering oligonucleotides speciﬁc for GnT-V were designed
on the Takara Bio website (http://www.takara-bio.co.jp/) and the oligo-
nucleotide sequences used in the construction of the siRNA vector were
as follows: 5 0-GATCCGTTCATTGGCGGAAATTCGTTTCAAGA-
GAACGAATTTCCGCCAATGAACTTTTTTAT-3 0 and 5 0-CGA-
TAAAAAAGTTCATTGGCGGAAATTCGTTCTCTTGAAACGA-
ATTTCCGCCAATGAACG-3 0. The oligonucleotides were annealed
and then ligated into BamHI/ClaI sites of the pSINsi-hU6 vector (Ta-
kara Bio). A retroviral supernatant was obtained by transfection of
human embryonic kidney 293 cells using a Retrovirus Packaging Kit
Ampho (Takara Bio) according to the manufacturer’s protocol.
CHP134 cells, a humanNBL cell line, were infected with the viral super-
natant, and the cells were then selected with 0.5 mg/ml G418 for 2–3
weeks. Stable GnT-V-knockdown clones were selected and conﬁrmed
by GnT-V activity and gene expression. Quantitative real-time PCR
analyses of GnT-V mRNA expression in these clones were performed
with a Smart Cycler II System and the SYBR premix Taq (Takara
Bio). RT was carried out at 42 C for 10 min, followed by 95 C for
2 min using random primers, followed by PCR for 50 cycles at 95 C
for 5 s and 60 C for 20 s with the following primers: 5 0-AAG-
CAGGTGTGCCAGGAGAG-3 0 and 5 0-GTCAAAGGAGGGCAC-
CAGGA-30. Normalization of the data was performed using the
GAPDH mRNA levels.
2.6. Analysis of retinoic acid-induced apoptosis
Parent, mock, and GnT-V-knockdown CHP134 cells were plated
on 10 cm culture dishes at 5 · 105 cells in RPMI1640 supplemented
with 10% fetal bovine serum, 100 U/ml penicillin, and 0.1 mg/ml
streptomycin. After incubation for 24 h, the conditioned media were
changed with fresh medium containing various concentrations of
all-trans retinoic acid (Sigma). The cells were washed twice with
PBS and harvested at the indicated times. Retinoic acid-induced
apoptosis was estimated by detecting the cleavage of poly ADP-ri-
bose polymerase (PARP) in whole cell lysates by Western blot
analysis using a human speciﬁc anti-cleaved PARP (Asp214) anti-
body (Cell Signaling Technology). As a loading control, anti-
ERK1/2 (p44/42 MAP Kinase Antibody, Cell Signaling Technology)
was used.
2.7. Viability assay of retinoic acid-treated cells
The parent, mock, and GnT-V-knockdown CHP134 cells were
seeded on a 96-well plate at 3 · 103 cells/well for 24 h prior to the ret-
inoic acid treatment. The cells were then incubated with or without ret-
inoic acid at the indicated concentrations for 3 days. Cell viability was
assayed using a Cell Counting Kit-8 (Dojindo, Kumamoto, Japan)
according to the manufacture’s instructions. All experiments were car-
ried out in triplicate for each data point.3. Results
3.1. Association between higher expression levels of GnT-V
mRNA and favorable prognosis in primary NBLs
To assess the association between GnT-V or GnT-IX
mRNA expression and the prognosis of the NBLs, we ﬁrst per-
formed semiquantitative RT-PCR analyses using 16 favorable
and 16 unfavorable NBLs. As shown in Fig. 1, GnT-V was
preferentially expressed in most of the favorable NBLs, while
no obvious diﬀerence in GnT-IX expression was found
between favorable and unfavorable NBLs. Table 1 shows
quantitative data for GnT-V and GnT-IX mRNA in 126 pri-
mary NBLs with tumor stages (1, 2, 4s versus 3, 4). GnT-V
expression was signiﬁcantly increased in NBLs at favorable
stages (P = 0.021), and was correlated well with higher expres-
sion of TrkA (P = 0.010). On the other hand, GnT-IX expres-
sion was marginally associated with the stages.
3.2. GnT-V activities in various human NBL cell lines
To determine whether the expression level of GnT-V is also
increased in NBL cells, the activities of GnT-V in various hu-
man NBL cell lines were examined. As shown in Fig. 2A, each
cell line expressed GnT-V activity at distinct levels. The
CHP134 cells showed the highest GnT-V activity among the
10 NBL cell lines used in this study. It is known that the cell
line is highly sensitive to the induction of apoptosis by all-trans
retinoic acid [14,15]. In fact, it is thought that favorable NBLs
usually express higher levels of TrkA, and tend to regress spon-
taneously due to apoptosis. As shown in Fig. 2B, in CHP134
cells that had been treated with retinoic acid at a concentration
of 1 lM or 5 lM, PARP cleavage, a marker for apoptosis, oc-
curred, which is one of the main cleavage targets of caspase-3
Fig. 2. GnT-V activities in various NBL cell lines and retinoic acid-
induced apoptosis of CHP134 cells. (A) GnT-V activity of each of the
NBL cells was measured using a whole cell lysate as an enzyme source.
(B) Western blot of whole cell lysate of CHP134 cells. Cell apoptosis
was observed by staining of cleaved PARP after treatment of retinoic
acid (RA) at indicated concentrations and times. The expression levels
of ERK1/2 were conﬁrmed as a loading control.
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of the eﬀects of GnT-V on apoptosis.
3.3. Knockdown of GnT-V expression in CHP134 cells
We prepared a retroviral siRNA vector containing a small
hairpin construct capable of generating a duplex RNAi oligo-
nucleotide corresponding to human GnT-V. After retroviral
infection, CHP134 cells were selected based on their resistance
to G418, and clones with decreased GnT-V activities were cho-
sen. The GnT-V activities were eﬀectively downregulated by
80%, compared with those in parent or mock cells (Fig. 3A),
while GnT-III activity, as a control, showed no signiﬁcant
changes between those cells. A quantitative real-time PCR
analysis also indicated the downregulation of RNAi-directedFig. 3. Enzyme activities and mRNA expression levels in siRNA-mediated
CHP134 cells. The microsomal fraction was used as an enzyme source i
Quantitative analysis was performed by real-time PCR. Pa, parent cells; MoGnT-V mRNA expression in these cells (Fig. 3B). It is note-
worthy that the cells in GnT-V-knockdown clones showed
more spreading on the culture dishes, rather than the spindle
shapes of the parent and mock cells (Fig. 4), suggesting that
GnT-V may aﬀect cellular cytoskeletal formation. In fact,
Guo et al. reported that the overexpression of GnT-V in hu-
man HT1080 cells resulted in a decrease in cell adhesion on
ﬁbronectin [18].
3.4. Decreased susceptibility to retinoic acid-induced apoptosis in
GnT-V-knockdown cells
To evaluate the eﬀects of GnT-V expression on susceptibility
to apoptosis induction in CHP134 cells, we examined cell
viabilities in the presence of retinoic acid. After treatment with
diﬀerent concentrations of retinoic acid, we found that GnT-V-
knockdown cells (KD1 and KD2 in Fig. 5A) had a tendency to
be resistant to stimulation by retinoic acid. We further assessed
the apoptosis level in retinoic acid-treated cells by PARP
cleavage. The GnT-V-knockdown cells showed dramatically
reduced levels of PARP cleavage (Fig. 5B). Collectively, these
results suggest that GnT-V may sensitize cells to apoptotic sig-
nals, which partly contribute to the favorable prognosis of
NBL.4. Discussion
Previous studies demonstrated that an increased amount of
b1,6-branched oligosaccharides, formed by the action of
GnT-V, are correlated with metastatic potential [2], and this
has been shown to be a marker of tumor progression in human
breast and colon neoplasia [19], and a prognostic marker in
human colorectal carcinoma [20,21]. However, it is not always
the case, as evidenced by the fact that Dosaka-Akita et al.
reported that the lower expression of GnT-V is associated with
a shorter survival and a poor prognosis in non-small cell lung
cancers [22]. The present study also suggested that a higher
expression of GnT-V is related to a favorable prognosis in
NBLs.
GnT-V and GnT-IX, two closely related glycosyltransfe-
rases, are expressed in both the adult and fetal brain [7,9].
GnT-V expression is upregulated in E9.5 embryos, and is thenGnT-V-knockdown cells. (A) GnT-V activities of GnT-V-knockdown
n the assay. (B) mRNA expression of GnT-V in knockdown cells.
, mock cells; KD1 and KD2, GnT-V-knockdown cells.
Fig. 4. Morphological changes in GnT-V-knockdown cells. Parent (Pa), mock (Mo), and GnT-V-knockdown CHP134 cells (KD1, KD2) were plated
on culture dishes and incubated for 24 h in culture media. Cell shapes were observed by phase contrast microscopy.
Fig. 5. Cell viabilities and PARP cleavage in retinoic acid-treated GnT-V-knockdown cells. Cell viabilities of parent (Pa), mock (Mo), and GnT-V-
knockdown cells (KD1, KD2) were performed as described in Section 2 (A). Cells were treated with retinoic acid at the indicated concentrations for 3
days. *P < 0.05. (B) Western blot of cleaved PARP in a cell lysate using an anti-cleaved PARP antibody. Cells were harvested for analysis 24 h after
retinoic acid-treatment.
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cell layers and the neuroepithelium of the developing central
nervous system [9]. On the other hand, GnT-IX is dominantly
expressed in the human and mouse brain [7,23]. Thus, we at-
tempted to examine the expressions of GnT-V and GnT-IX
in primary NBL tissues.
The frequent gain of the chromosome 17q has been reported
to be associated with a poor prognosis [24], and the preferen-
tial gain of the region from 17q22-qter indicated a dosage eﬀect
that provides a selective advantage to be aggressive NBLs [25].The gene responsible for the selective advantage is unknown,
but a candidate gene that is a member of the inhibitor of apop-
tosis proteins, survivin, which is mapped to 17q25, has been re-
ported [14]. Although the GnT-IX gene is also mapped to
17q25 [7], an unequivocal correlation with prognosis was not
observed in this study. Interestingly, a signiﬁcant association
between expression levels of GnT-V mRNA and the prognosis
of 126 NBL patients was observed by real-time PCR analysis.
Several human NBL cell lines also consistently express GnT-V.
To understand the molecular mechanism associated with the
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of NBLs, we selected CHP134 cells as a cell model. Since the
cell line is highly sensitive to retinoic acid-induced apoptosis
[14,15], we compared the eﬀects of retinoic acid on apoptosis
between parent cells and GnT-V-knockdown cells.
In fact, GnT-V-knockdown cells showed a tendency to es-
cape from retinoic acid-induced apoptosis, as conﬁrmed by a
cell viability assay and the extent of cleaved PARP, supporting
the notion that a higher expression of GnT-V is correlated with
a favorable prognosis of NBLs. It is noteworthy that a prom-
inent morphological alteration with increased spreading was
observed in the GnT-V-knockdown cells. The altered charac-
teristic of GnT-V-knockdown CHP134 cells observed in this
study is consistent with those of previous studies [3,18,26,27].
The overexpression of GnT-V enhances the metastatic poten-
tial in several cell types with reduced cell-matrix adhesion
and increased motility [3,18,26]. Furthermore, GnT-V expres-
sion in human glioma cell line U-373 MG sensitizes these cells
to drag-induced apoptosis [28]. Conversely, GnT-V null mouse
embryonic ﬁbroblasts exhibited an enhanced adhesion and
spreading with associated reduced cell migration [27]. In addi-
tion, no signiﬁcant eﬀect of GnT-V overexpression was ob-
served on apoptotic behavior in ﬁbrosarcoma HT1080 cells,
a ﬁbroblast cell line, but a similar phenotypic change with re-
gard to adhesion and migration has been reported [18]. In gen-
eral, the adhesion of epithelial cells to extracellular matrices is
weaker than that of ﬁbroblast cells, and such adhesion is
thought to be synergized with the signals of growth factor
receptors for modulating cell proliferation and apoptosis.
Therefore, we speculate that the GnT-V-induced decrease in
cell adhesion could be a plausible factor responsible for the
favorable prognosis in NBLs.
In conclusion, a correlation between higher expression levels
of GnT-V with a favorable prognosis of NBL patients was
found, and GnT-V may cause these tumors to regress by
increasing their susceptibility to apoptosis.
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